What is the intrinsic value of ORMP?
As of 2026-10-24, the Intrinsic Value of Oramed Pharmaceuticals Inc (ORMP) is
21.36 USD. This ORMP valuation is based on the model Peter Lynch Fair Value.
With the current market price of 4.13 USD, the upside of Oramed Pharmaceuticals Inc is
417.24%.
Is ORMP undervalued or overvalued?
Based on its market price of 4.13 USD and our intrinsic valuation, Oramed Pharmaceuticals Inc (ORMP) is undervalued by 417.24%.
21.36 USD
Intrinsic Value
ORMP Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(256.55) - (19.35) |
(35.31) |
-954.9% |
| DCF (Growth 10y) |
(19.66) - (239.55) |
(34.51) |
-935.7% |
| DCF (EBITDA 5y) |
(5.00) - (6.92) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(7.36) - (9.58) |
(1,234.50) |
-123450.0% |
| Fair Value |
21.36 - 21.36 |
21.36 |
417.24% |
| P/E |
23.07 - 168.76 |
71.55 |
1632.4% |
| EV/EBITDA |
(0.99) - (1.16) |
(1.00) |
-124.1% |
| EPV |
(4.01) - (5.38) |
(4.70) |
-213.7% |
| DDM - Stable |
52.12 - 492.83 |
272.47 |
6497.4% |
| DDM - Multi |
22.90 - 172.48 |
40.79 |
887.7% |
ORMP Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
169.04 |
| Beta |
0.80 |
| Outstanding shares (mil) |
40.93 |
| Enterprise Value (mil) |
153.80 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.10% |
| Cost of Debt |
5.00% |
| WACC |
5.70% |